CME 6 Session - EANM'16

Neuroimaging: Alzheimer's Disease and Amyloid PET: News and Views 2016

Educational objectives:
  1. To understand the role of amyloid imaging in the diagnosis of Alzheimer’s disease
  2. To understand the characteristics of several amyloid tracers
  3. To understand when quantification of amyloid imaging is needed

One of the neuropathological characteristics of Alzheimer’s disease is the accumulation of amyloid-B. The development of carbon-11 labelled Pittsburgh compound-B ([11C]PIB) about a decade ago provided a means for imaging amyloid load in vivo. In recent years, several fluorine-18 labelled amyloid tracers have been brought to the market. Therefore, it is no surprise that amyloid imaging has become one of the main clinical applications of PET. Amyloid positivity/negativity has become a valuable addition to the armamentarium for the (differential) diagnosis of Alzheimer’s disease. In addition, these tracers are used in monitoring progression of disease and response to disease (amyloid) modifying agents. Given that several tracers, all with their own characteristics, are available, it is timely to summarise current knowledge and future prospects. In addition, to avoid obsolete studies in the near future, it is important to realize when qualitative imaging is sufficient and when quantitative analyses are needed.

Key Words:

Alzheimer’s disease, Amyloid imaging, PET

User action required
If you have the permission to view this publication, please log in.